秦书艳，沈 磊，力 强



·临床报告·

玻璃体腔内注射康柏西普治疗视网膜静脉阻塞继发黄斑水肿

秦书艳，沈 磊，力 强

•METHODS: A total of 22 patients with macular edema secondary to retinal vein occlusion were treated in our hospital during January 2016 to Marth 2016. A total of 22 patients were given three intravitreal injections of Conbercept 0.05mL (0.5mg). Defore and after treatment, best-corrected visual acuity, fundus photography，fundus fluoreseein angiograph(FFA)，optical coherence tomography(OCT)were examined.

•RESULTS: A total of 22 patients were treated with intravitreal injection of Conbercept had different degrees of increase in the mean visual acuity at 1wk, 1, 2 and 3mo. The difference is statistically significant (P<0.05). OCT images show that the thickness of the central retinal thickness of the macular becomes thinner, and the difference is statistically significant (P<0.05). The FFA at 3mo showed a significant reduction in retinal leakage, obvious absorption of retinal hemorrhage.

•CONCLUSION: Intravitreal injection of anti-VEGF drugs Conbercept is an effective way to treat macular edema secondary to retinal vein occlusion, it is worth to promot, but the long-term efficacy and drug injection frequency still need to study further.

目的：观察玻璃体腔内注射康柏西普治疗视网膜静脉阻塞(retinal vein occlusion，RVO)继发黄斑水肿的临床效果及安全性。

方法：回顾性观察我院2016-01/03间收治的RVO继发黄斑水肿的患者22例22眼，3mo内给予3次玻璃体腔内注射康柏西普0.05mL(0.5mg),比较治疗前后患者的视力变化情况，光学相干断层扫描(OCT)检查，眼底荧光造影(FFA)及眼底出血吸收情况。

结果:所选患者玻璃体内注射康柏西普在1wk,1、2、3mo后平均视力均有不同程度的提高，差异有统计学意义(P<0.05)。OCT图像显示黄斑中心凹视网膜厚度明显变薄，与治疗前相比差异具有统计学意义(P<0.05)。治疗后3mo检查FFA显示视网膜渗漏明显减轻，眼底出血明显吸收。

结论：玻璃体腔内注射抗VEGF药物康柏西普治疗RVO继发的黄斑水肿疗效肯定，但远期疗效及注射药物的频率尚需进一步观察与探讨。

视网膜静脉阻塞；黄斑水肿； 康柏西普

引用：秦书艳，沈磊，力强.玻璃体腔内注射康柏西普治疗视网膜静脉阻塞继发黄斑水肿.国际眼科杂志2016;16(12):2329-2331

0引言

视网膜静脉阻塞(retinal vein occlusion， RVO)的发病机制尚不完全明确，多数学者认为是由于动脉供血不足，静脉壁受损以及异常的血流所致。RVO最常见的类型视网膜分支静脉阻塞(BRVO),其发病率0.6%～1.1%,其次是视网膜中央静脉阻塞(CRVO)，其发病率0.1%～0.4%[1]。黄斑水肿是其最常见的并发症，也是造成视力损害的最重要原因。数个多中心的研究结果表明，抗VEGF治疗可显著减少视网膜层间积液，有利于出血吸收和黄斑水肿的消退[2-3]。本文采用玻璃体腔内注射抗VEGF药物康柏西普治疗RVO继发黄斑水肿并对其疗效进行观察。

1对象和方法

1.1对象 选取2016-01/03在我院门诊就诊的RVO合并黄斑水肿的患者22例22眼，其中男16例，女6例，年龄36～68岁；……